- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03945123
Effects of Red Ginseng on Liver Function
May 7, 2019 updated by: Ki Tae Suk, Chuncheon Sacred Heart Hospital
Effect of Korea Red Ginseng on Non-alcoholic Fatty Liver Disease
Korea Red Ginseng (KRG) has effect on liver function
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Korea Red Ginseng (KRG) has been known as a natural product with anti-inflammatory effect in liver disease.
Gut microbiota plays an important roles in the pathophysiology of nonalcoholic statohepatitis (NASH).
We evaluated the effect of KRG on the pathophysiology of NASH
Study Type
Interventional
Enrollment (Actual)
94
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kangwon
-
Chuncheon, Kangwon, Korea, Republic of
- ChuncheonSHH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 61 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- AST or ALT level > 50 IU/L
Exclusion Criteria:
- Viral hepatitis
- Alcoholic hepatitis
- Autoimmune hepatitis
- Pancreatitis
- Hemochromatosis
- Wilson's disease
- Drug induced liver injury
- Cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ginseng trial
compare experimental group to controlled group
|
Red ginseng tablet 120g
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Liver enzyme
Time Frame: 1year
|
Decrease liver enzyme level
|
1year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Ki Tae Suk, PhD.Md., Chuncheon Sacred Heart Hospital
- Principal Investigator: Jun Seok, MD., Chuncheon Sacred Heart Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2018
Primary Completion (Actual)
December 31, 2018
Study Completion (Actual)
December 31, 2018
Study Registration Dates
First Submitted
May 3, 2019
First Submitted That Met QC Criteria
May 7, 2019
First Posted (Actual)
May 10, 2019
Study Record Updates
Last Update Posted (Actual)
May 10, 2019
Last Update Submitted That Met QC Criteria
May 7, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RIVER
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Not yet
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Dysfunction
-
Loma Linda UniversityWithdrawnLiver Graft Dysfunction
-
National Cancer Institute (NCI)Completed
-
University of AthensCompleted
-
Taipei City HospitalNational Yang Ming UniversityCompletedLiver DysfunctionTaiwan
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Bausch Health Americas, Inc.CompletedLiver DysfunctionUnited States
-
Chong Kun Dang PharmaceuticalCompletedLiver DysfunctionKorea, Republic of
-
University of AlbertaRecruitingLiver DysfunctionUnited States, Australia, Canada, Poland, United Kingdom
-
Zhejiang Medicine Co., Ltd.Huashan HospitalCompleted
-
PfizerCompletedMild Hepatic Dysfunction | Moderate Hepatic DysfunctionSouth Africa
Clinical Trials on Red ginseng
-
Unity Health TorontoHeart and Stroke Foundation of CanadaCompletedHypertension | Blood Pressure | Endothelial FunctionCanada
-
EuroPharma, Inc.Scientific Center of Drug and Medical Technologies Expertise of the Ministry... and other collaboratorsSuspended
-
Shanghai Jiao Tong University School of MedicineRenJi Hospital; Beijing Obstetrics and Gynecology Hospital; Foshan Fuxing Changcheng... and other collaboratorsRecruitingAntioxidative Stress | Healthy AgeingChina
-
The Korean Society of GinsengCompleted
-
Daegu Catholic University Medical CenterThe Korean Society of GinsengCompletedHypertensionKorea, Republic of
-
The Korean Society of GinsengCompleted
-
EuroPharma, Inc.Completed
-
Korea Ginseng CorporationNutrasource Pharmaceutical and Nutraceutical Services, Inc.RecruitingCardiovascular Diseases | Platelet Aggregation | Vasodilation | Blood Pressure DisordersUnited States
-
Chuncheon Sacred Heart HospitalCompleted
-
Chonbuk National University HospitalCompleted